Resource table.Unlabelled TableUnique stem cell line identifierCSSi007-A (4383)Alternative name(s) of stem cell line*Joub07 cl1*InstitutionIRCCS Casa Sollievo della SofferenzaContact information of distributor*Jessica ROSATI*[*j.rosati\@css-mendel.it*](mailto:j.rosati@css-mendel.it){#ir0005}Type of cell line*iPSC*Origin*Human*Additional origin info*Applicable for human iPSCAge: 27 yrsSex: MaleEthnicity if known: Caucasian/Italian*Cell Source*Dermal Fibroblasts*Method of reprogramming*Non integrating episomal vectors*Genetic Modification*NO*Type of Modification*N/A*Associated disease*Joubert Syndrome*Gene/locus(*AHI1*):c.2168G \> A/6q23.3Method of modification*N/A*Name of transgene or resistance*N/A*Inducible/constitutive system*N/A*Date archived/stock date*09/01/2015*Cell line repository/bank*N/A*Ethical approval*Casa Sollievo della Sofferenza Ethical Committee, approval number: 2292/DS*

Resource utility {#s0005}
================

Joubert Syndrome is a rare, genetically heterogeneous disorder whose complexity makes it difficult to associate phenotype to genotype. The derivation of induced pluripotent cells (iPSCs) from individuals suffering from JS offers the possibility of studying this multi-organ disease *in vitro*, differentiating the iPSCs into the various cell types that are affected.

Resource details {#s0010}
================

The distinctive hallmark of Joubert Syndrome (JS) is the "molar tooth sign" (MTS), a complex midbrain-hindbrain malformation visible on brain imaging. The phenotypic presentation is extremely variable. The core neurological features include developmental delay, breathing abnormalities in the neonatal period, hypotonia, abnormal eye movements, ataxia and intellectual disability; these can be variably associated to defects in other organs, such as the retina, kidney and liver. One causative gene of JS is the Abelson helper integration site 1 (*AHI1*) gene, which encodes a cytoplasmic multidomain protein localized in the basal body of the primary cilium, also known as jouberin, composed of an N-terminal coiled-coil domain, WD40 repeats and a C-terminal SH3 domain ([@bb0005]; [@bb0025]; [@bb0020]). The patient presented here, a 27-year old male, was found to carry a homozygous pathogenic missense variant in *AHI1 (c.2168G* *\>* *A, p. Arg723Gln)*. Skin fibroblasts from the patient were reprogrammed into iPSCs, using three non-integrative episomal vectors containing the reprogramming factors *OCT 3/4, SOX2, L-MYC, KLF4, LIN28, SHP53*. The presence of the disease-related mutation (AHI1): c.2168G \> A in fibroblasts was confirmed by Sanger sequencing ([Fig. 1](#f0005){ref-type="fig"}A) in the generated iPSCs. JS iPS cell colonies displayed a typical morphology of human pluripotent stem cells and growth behavior ([Fig. 1](#f0005){ref-type="fig"}B). We also examined the presence of episomal plasmid DNA in the established iPSCs, using primers specific to a sequence that is common in all three reprogramming plasmids and we observed that after 10 passages the iPSCs were devoid of vector sequences as shown by qRT-qPCR, using, as positive control, the fibroblasts after one week from episomal nucleofection ([Fig. 1](#f0005){ref-type="fig"}C). We confirmed the genomic stability of iPSCs through karyotype, which provided a normal diploid 46, XY chromosome arrangement without any detectable abnormalities ([Fig. 1](#f0005){ref-type="fig"}D). Staining for endogenous marker TRA-1-60 and OCT-4 demonstrated the pluripotency of these iPSCs ([Fig. 1](#f0005){ref-type="fig"}E), that was confirmed through qRT-PCR ([Fig. 1](#f0005){ref-type="fig"}F). The *in vitro* spontaneous differentiation potential was demonstrated by the formation of embryoid bodies (EBs) ([Fig. 1](#f0005){ref-type="fig"}G) and teratoma formation *in vivo* ([Fig. 1](#f0005){ref-type="fig"}H). qRT-PCR analysis showed the endogenous expression of the three germ layers markers ([Fig. 1](#f0005){ref-type="fig"}I). PCR-based detection tests confirmed the absence of Mycoplasma contamination at this stage ([Supplementary Fig. 1](#f0010){ref-type="graphic"}). In addition, Short Tandem Repeat (STR) profiling confirmed that these iPSC lines had the same genetic identity with respect to the donor\'s fibroblasts (Data available with the authors).

Materials and methods {#s0015}
=====================

Skin biopsy and fibroblast reprogramming {#s0020}
----------------------------------------

The skin biopsy was mechanically processed and maintained in fibroblast medium (DMEM high glucose, 20% FBS, 2mML-glutamine and 1% penicillin--streptomycin (all reagents from Sigma Aldrich)). Subsequently, 1 × 105 fibroblasts were nucleofected with 3 μg 1:1:1 mix of the episomal plasmids pCXLE-hUL (Addgene \#27080), pCXLEhSK (Addgene \#27078) and pCXLE-hOCT4-shp53 (Addgene \#27077). On day 7, the nucleofected fibroblasts were counted, plated on Matrigel (1:100) (BD Biosciences) and cultured in NutristemXF medium (Biological Industries). The emergent hiPSC colonies were picked according to their hESC-like colony morphology and expanded under feeder-free conditions. Absence of mycoplasma contamination was verified using N-Garde Mycoplasma PCR kit (EuroClone) which detects the presence of mycoplasmas in cell culture supernatants by PCR amplification using a reaction mixture containing all the ingredients necessary for PCR, positive control is provided by the kit. 1Kb was used ad ladder in the running. After ten passages, the clearance of the exogenous reprogramming factors was confirmed by qRT-PCR ([Table 1](#t0005){ref-type="table"}).Fig. 1Characterization of CSSi007-A (4383) A. Detection of homozygous mutation: green arrow indicates the mutation site (AHI1):c.2168G\>A. B. Phase contrast imaging of the morphology of iPSC line. C. Transgenes expression analysis through qRT-PCR demonstrates the loss of episomal vectors during amplification. D. Cytogenetic analysis showing the normal karyotype of CSSi007-A (4383). E. Representative immunofluorescent stainings showing the expression of stem cell markers such as OCT-4 (green) and TRA-1-60 (red), nuclei was counterstained with DAPI. F. qRT-PCR shows the expression of endogenous stem cell markers in JS iPSCs with respect to fibroblasts used as reference. G. Spontaneous differentiation of JS iPSC in embryoid bodies. H. The injection of iPS cells produced teratoma in vivo. I. Differentation marker expression analysis. Embryoid bodies express the three germ layer markers.Fig. 1Table 1Characterization and validation.Table 1ClassificationTestResultDataMorphologyPhotography*Normal*[Fig. 1](#f0005){ref-type="fig"}BPhenotypeImmunocytochemistry*Staining of pluripotency markers: Oct4; Tra-1-60.*[Fig. 1](#f0005){ref-type="fig"}C, E, FqRT-PCR*Expression of pluripotency markers: OCT4, LIN28, L-MYC, KLF4, SOX2*GenotypeKaryotype (G-banding) and resolution*46 XY, Resolution 450--500*[Fig. 1](#f0005){ref-type="fig"}DIdentitySTR analysis*Tested*Data available with the authorsMicrobiology and virologySequencing*Homozygous mutation*[Fig. 1](#f0005){ref-type="fig"}AMycoplasma*Mycoplasma tested* by N-Garde Mycoplasma PCR kit (EuroClone) is Negative.[Supplementary Fig. 1](#f0010){ref-type="fig"}Differentiation potential MorphologyEmbryoid body formation and Teratoma formation*Genes expressed in embryoid bodies: SOX1, NESTIN, PAX6, EOMES, T, GATA4, FOXA2, SOX17*[Fig. 1](#f0005){ref-type="fig"}G, H, I*Proof of three germ layers formation.*Photography*Normal*[Fig. 1](#f0005){ref-type="fig"}BPhenotypeImmunocytochemistry*Staining of pluripotency markers: Oct4; Tra-1-60.*[Fig. 1](#f0005){ref-type="fig"}C, E, FqRT-PCR*Expression of pluripotency markers: OCT4, LIN28, L-MYC, KLF4, SOX2*GenotypeKaryotype (G-banding) and resolution*46 XY, Resolution 450--500*[Fig. 1](#f0005){ref-type="fig"}DDonor screeningHIV 1 + 2 Hepatitis B, Hepatitis C*N/A*Genotype additional infoBlood group genotyping*N/A*HLA tissue typing*N/A*

Embryoid body formation {#s0025}
-----------------------

For the generation of EBs, mechanically detached iPSC were plated in Petri dishes in NutristemXF medium, which was substituted with differentiation medium: DMEM/F12, 20% KOSR (Gibco), 0,1 mM NEAA, 0.1 mM β-mercaptoethanol, 1% Pen/Strep the following day. Fourteen days later, EBs were pelletted and RNAs were extracted for qRT-PCR analysis.

Teratoma formation {#s0030}
------------------

Approximately iPSCs from six well plates combined with a Matrigel substrate (Corning, Inc., USA) were injected into the right flank of nude mice. After 1 month, tumors were collected for histological analysis to check for their *in vivo* differentiation capacity into derivatives of all three germ layers.

Real-Time PCR analysis {#s0035}
----------------------

Total RNAs were extracted using Trizol reagent (Life Technology) and cDNA synthesized using the High capacity cDNA RT (Life Technology) following manufacturer\'s recommendations. qPCR analysis was performed in three minimum independent biological experiments with TaqMan primers ([Table 2](#t0010){ref-type="table"}) for three germ layers (Thermo Fischer Scientific) and Sybergreen primers ([Table 2](#t0010){ref-type="table"}) for stemness markers according to the manufacturer\'s protocol. The expression ratio of the target genes was calculated by using the 2^−ΔΔCt^ method, considering 18S as reference gene.Table 2Reagents details.Table 2Antibodies used for immunocytochemistry/flow-citometryAntibodyDilutionCompany Cat \# and RRIDPluripotency Markers*Rabbit anti-OCT41:100Life technologies (A13998)Mouse anti-TRA-1-601:100Life technologies (411000)*Secondary antibodies*anti-Rabbit AlexaFluor 4881:10000Invitrogen (A11034)anti-Mouse AlexaFluor 5551:10000Invitrogen (A21422)*  Sybr Green Primers used for qPCRTargetForward/Reverse sequence (5′-3′)Episomal genes*eOCT4Fwd: CAT TCA AAC TGA GGT AAG GGRev: TAG CGT AAA AGG AGC AAC ATA GeKLF4Fwd: CCA CCT CGC CTT ACA CAT GAA GARev: TAG CGT AAA AGG AGC AAC ATA GeLIN28Fwd: AGC CAT ATG GTA GCC TCA TGT CCG CRev: TAG CGT AAA AGG AGC AAC ATA GeL-MYCFwd: GGC TGA GAA GAG GAT GGC TACRev: TTT GTT TGA CAG GAG CGA CAA TeSOX2Fwd: TTC ACA TGT CCC AGC ACT ACC AGARev: TTT GTT TGA CAG GAG CGA CAA T*Pluripotency markers*OCT4Fwd: CCC CAG GGC CCC ATT TTG GTA CCRev: ACC TCA GTT TGA ATG CAT GGG AGA GCLIN28Fwd: AGC CAT ATG GTA GCC TCA TGT CCG CRev: TCA ATT CTG TGC CTC CGG GAG CAG GGT AGGL-MYCFwd: GCG AAC CCA AGA CCC AGG CCT GCT CCRev: CAG GGG GTC TGC TCG CAC CGT GAT GSOX2Fwd: TTC ACA TGT CCC AGC ACT ACC AGARev: TCA CAT GTG TGA GAG GGG CAG TGT GC*House-Keeping Gene*β-ACTINFwd: GGC ATC CTC ACC CTG AAG TARev: GGG GTG TTG AAG GTC TCA AA*  TaqMan primers used for qPCRTargetProbeDifferentation markers*SOX1Hs01057642_s1NESTINHs04187831_g1PAX6Hs00240871_m1THs00610080_m1EOMESHs00172872_m1GATA4Hs00171403_m1FOXA2Hs00232764_m1SOX17Hs00751752_s1β-ACTINHs 99999903_m1*

Immunofluorescence staining {#s0040}
---------------------------

Cells were fixed using 4% paraformaldehyde and stained. The cells were incubated with Blocking Buffer (PBS containing 20% Normal Goat Serum, 0.1% Triton X-100) for 30 min at room temperature. Next, primary antibodies, listed in [Table 2](#t0010){ref-type="table"}, diluted in blocking buffer were added and incubated O/N at 4 °C. After extensive washing, Alexa Fluor 594- and/or Alexa Fluor 488-conjugated secondary antibodies were added 1 h at room temperature. Cellular nuclei were counterstained with DAPI. Microphotograps were taken using a Nikon C2 fluorescence microscope and NIS Elements 1.49 software.

Karyotype analysis {#s0045}
------------------

Pluripotent cells were cultured in T25 flasks coated with Matrigel in Nutristem medium for 2--3 days. Karyotype analysis of metaphase chromosomes were performed using G-banding. Fifteen metaphases were counted and three karyograms analyzed.

STR analysis {#s0050}
------------

Fibroblasts and iPSCs DNA was extracted by Dneasy blood and tissue kit (QIAGEN). PCR amplification of 19 distinct STRs (D13S252, D13S305, D13S634, D13S800, D13S628, D18S819, D18S535, D18S978, D18S386, D18S390, D21S11, D21S1437, D21S1409, D21S1442, D21S1435, D21S1446, DXS6803, XHPRT, DXS1187) was carried out using the QST\*Rplusv2 kit (Elucigene Diagnostics), PCR products were separated on an ABI Prism 3130 DNA sequencer and analyzed by GeneMapper version 4.0 (Applied Biosystems).
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